Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$76.01

3.38 (4.65%)

14:25
09/29/19
09/29
14:25
09/29/19
14:25

Seattle Genetics, Astellas announce results from Phase 1 clinical trial EV-103

Seattle Genetics and Astellas Pharma announced initial results from the phase 1 clinical trial EV-103. 45 patients were evaluated for safety with the combination of the investigational agent enfortumab vedotin and the immune therapy pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. The study met outcome measures for safety and exhibited encouraging clinical activity for this platinum-free combination in a first-line setting. Enfortumab vedotin is a first-in-class antibody drug conjugate that targets Nectin-4, a protein present on almost all urothelial tumor cells and associated with cancer formation. 51% of patients had an adverse event greater than or equal to Grade 3. Among these events, an increase in lipase was the most frequent. Four patients discontinued treatment due to treatment-related adverse events, most commonly peripheral sensory neuropathy. There was one death deemed to be treatment-related by the investigator attributed to multiple organ dysfunction syndrome. 11% of patients had treatment-related immune-mediated adverse events of clinical interest greater than or equal to Grade 3 that required the use of systemic steroids. None of the adverse events of clinical interest were Grade 5 events. The data demonstrated the combination of enfortumab vedotin plus pembrolizumab shrank tumors in the majority of patients, resulting in a confirmed objective response rate of 71%. The complete response rate was 13%. 58% of patients had a partial response and 22% had stable disease. 91% of responses were observed at the first assessment. Enfortumab vedotin is currently under review by the U.S. Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in a neoadjuvant/adjuvant, locally advanced or metastatic setting.

SGEN Seattle Genetics
$76.01

3.38 (4.65%)

09/12/19
OPCO
09/12/19
UPGRADE
OPCO
Outperform
Seattle Genetics upgraded to Outperform from Perform at Oppenheimer
09/12/19
09/12/19
UPGRADE
Target $82

Outperform
Seattle Genetics upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
09/27/19
GSCO
09/27/19
UPGRADE
Target $100
GSCO
Buy
Seattle Genetics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter upgraded Seattle Genetics to Buy from Neutral and raised his price target for the shares to $100 from $78. The stock closed Thursday down 99c to $72.63. With continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, the analyst expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. He expects approval of enfortumab vedotin by the March 15, 2020 action data and is positive on Seattle's two-late stage assets, tucatinib in HER2+ metastatic breast cancer and tisotumab vedotin in metastatic cervical cancer, with results by year-end 2019 and the first half of 2020, respectively.
09/27/19
09/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Western Union (WU) upgraded to Buy from Neutral at Guggenheim with analyst Jeff Cantwell citing what he called the company's "positive" investor day where management outlined "a solid 3-year growth trajectory." 2. Applied Genetic (AGTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying the early XLRP data suggest potential for vision stabilization in peripherally treated patients and vision improvement in centrally treated patients. 3. Seattle Genetics (SGEN) upgraded to Buy from Neutral at Goldman Sachs with analyst Salveen Richter saying with continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, he expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. 4. Match Group (MTCH) upgraded to Outperform from In Line at Evercore ISI. 5. Texas Instruments (TXN) upgraded to Buy from Neutral at BofA/Merrill with analyst Vivek Arya saying he is positive on Texas Instruments' market share gains, stronger free cash flow returns, stronger positioning in growth areas such as 5G, Internet-of-Things, and Electric vehicles. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TSLA

Tesla

$253.68

-1.94 (-0.76%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Periodicals
Tesla sued over Model S door handle malfunction, CCN says »

The family of a man who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FITB

Fifth Third

$28.11

-0.195 (-0.69%)

14:20
10/23/19
10/23
14:20
10/23/19
14:20
Options
Calls lead puts 8:1 in Fifth Third Bancorp as writer opens position »

Calls lead puts 8:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

IBM

IBM

$134.05

0.02 (0.01%)

, GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

14:18
10/23/19
10/23
14:18
10/23/19
14:18
Periodicals
Google says computer achieves 'quantum supremacy,' Reuters reports »

Alphabet's Google…

IBM

IBM

$134.05

0.02 (0.01%)

GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

GOOG

Alphabet

$1,253.87

11.09 (0.89%)

MSFT

Microsoft

$136.15

-0.24 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/19
10/23
14:17
10/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/19
10/23
14:16
10/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$54.51

0.64 (1.19%)

, WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

14:12
10/23/19
10/23
14:12
10/23/19
14:12
On The Fly
Coca-Cola upgrade, Walgreens downgrade among today's top analyst calls »

Check out today's top…

KO

Coca-Cola

$54.51

0.64 (1.19%)

WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

SNAP

Snap

$13.23

-0.77 (-5.50%)

BIIB

Biogen

$277.71

-4.25 (-1.51%)

NOW

ServiceNow

$218.44

-9.82 (-4.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Coupon Rate data reported »

5-Yr Note Auction Coupon…

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Total Amount data reported »

5-Yr Note Auction Total…

SWM

Schweitzer-Mauduit

$39.78

1.11 (2.87%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Initiation
Schweitzer-Mauduit initiated  »

Schweitzer-Mauduit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARVN

Arvinas

$19.41

3.01 (18.35%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Hot Stocks
Arvinas spikes 17% after platform update including Protac trial data »

Earlier today, Arvinas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:04
10/23/19
10/23
14:04
10/23/19
14:04
Periodicals
WeWork plans to cut up to 4,000 jobs in turnaround, FT reports »

WeWork (WE) plans to cut…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

, CMCSK

Comcast

$0.00

(0.00%)

14:01
10/23/19
10/23
14:01
10/23/19
14:01
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$137.96

0.76 (0.55%)

MMM

3M

$167.62

0.06 (0.04%)

NOC

Northrop Grumman

$349.80

-2.61 (-0.74%)

RTN

Raytheon

$202.20

-2.69 (-1.31%)

BAX

Baxter

$87.71

0.68 (0.78%)

DOW

Dow Inc.

$47.27

0.45 (0.96%)

HSY

Hershey

$149.87

0.14 (0.09%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

LUV

Southwest

$53.25

0.355 (0.67%)

TROW

T. Rowe Price

$109.40

1.4 (1.30%)

SWK

Stanley Black & Decker

$153.29

1.98 (1.31%)

HBAN

Huntington Bancshares

$14.48

0.045 (0.31%)

CTXS

Citrix

$103.72

-0.38 (-0.37%)

TSCO

Tractor Supply

$94.34

0.12 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 12

    Dec

HMC

Honda

$26.63

0.015 (0.06%)

14:00
10/23/19
10/23
14:00
10/23/19
14:00
Periodicals
Honda to sell only electric, hybrid cars in Europe starting in 2022, CNN says »

Honda said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

, TSLA

Tesla

$255.10

-0.52 (-0.20%)

13:59
10/23/19
10/23
13:59
10/23/19
13:59
Earnings
Notable companies reporting after market close »

Notable companies…

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

TSLA

Tesla

$255.10

-0.52 (-0.20%)

PYPL

PayPal

$95.99

-1.41 (-1.45%)

MSFT

Microsoft

$136.25

-0.14 (-0.10%)

LVS

Las Vegas Sands

$59.16

0.58 (0.99%)

NOW

ServiceNow

$218.68

-9.58 (-4.20%)

F

Ford

$9.04

-0.025 (-0.28%)

LRCX

Lam Research

$233.15

-1.76 (-0.75%)

EBAY

eBay

$39.03

0.06 (0.15%)

ORLY

O'Reilly Automotive

$400.41

-0.16 (-0.04%)

XLNX

Xilinx

$95.26

-0.75 (-0.78%)

EFX

Equifax

$139.11

-0.15 (-0.11%)

ALGN

Align Technology

$217.63

4 (1.87%)

BMRN

BioMarin

$69.77

2.04 (3.01%)

FBHS

Fortune Brands

$58.73

0.22 (0.38%)

SLM

Sallie Mae

$9.10

0.04 (0.44%)

SAVE

Spirit Airlines

$37.74

0.49 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

HPE

HP Enterprise

$15.93

-0.03 (-0.19%)

13:55
10/23/19
10/23
13:55
10/23/19
13:55
Conference/Events
HP Enterprise to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Dec

AXON

Axovant Sciences

$0.00

(0.00%)

13:53
10/23/19
10/23
13:53
10/23/19
13:53
Recommendations
Axovant Sciences analyst commentary  »

Axovant Sciences price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$12.75

0.4 (3.24%)

13:45
10/23/19
10/23
13:45
10/23/19
13:45
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$13.27

-0.73 (-5.21%)

, FB

Facebook

$184.57

2.3 (1.26%)

13:40
10/23/19
10/23
13:40
10/23/19
13:40
On The Fly
#SocialStocks: Snap earnings beat, Facebook CEO testifies about Libra »

Welcome to…

SNAP

Snap

$13.27

-0.73 (-5.21%)

FB

Facebook

$184.57

2.3 (1.26%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

GOOG

Alphabet

$1,253.59

10.81 (0.87%)

GOOGL

Alphabet Class A

$1,251.72

10.64 (0.86%)

AMZN

Amazon.com

$1,757.06

-9.01 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 21

    Nov

  • 21

    Nov

ALXN

Alexion

$105.87

6.645 (6.70%)

13:37
10/23/19
10/23
13:37
10/23/19
13:37
Recommendations
Alexion analyst commentary  »

Alexion execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

13:35
10/23/19
10/23
13:35
10/23/19
13:35
General news
Treasury Action: the market took the good auction results in stride »

Treasury Action: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/23/19
10/23
13:17
10/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/23/19
10/23
13:16
10/23/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.